Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma.
BACKGROUND
Systemic treatment of metastatic renal cell carcinoma (mRCC) with targeted therapies became widely accepted; however, there are few patients who greatly benefit from immunochemotherapy (ICT). It is crucial to recognize these patients for individual treatment.


OBJECTIVE
Definition of protein patterns in tissue and serum from mRCC-patients to predict benefit from ICT.


METHODS
Twenty-five tissue samples and 59 sera were analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Protein peaks of interest were identified by 2D-PAGE and peptide mass fingerprinting. Validation was carried out by Western Blot and ELISA.


RESULTS
Protein patterns associated with therapy response were determined. Caveolin-1 (CAV-1) and plasminogen activator inhibitor 1 (PAI-1) were identified in tissue; serum amyloid A (SAA) and transthyretin (TTR) were found in serum.


CONCLUSIONS
Individual prediction of therapy benefit and selecting patients for ICT based on molecular biological profiles appear to be feasible in the future.
Walter
Martina
M
Department of Urology, University Hospitals Jena, Lessingstraße 1, 07743 Jena, Germany. martina.walter@med.uni-jena.de
Heinze
Christian
C
Steiner
Thomas
T
Pilchowski
Rico
R
von Eggeling
Ferdinand
F
Wunderlich
Heiko
H
Junker
Kerstin
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D051242:Caveolin 1 / Q000032:analysis*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000097:blood* / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000097:blood / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011228:Prealbumin / Q000032:analysis* / Q000378:metabolism; D011379:Prognosis; D040081:Protein Array Analysis; D012074:Remission Induction / Q000379:methods; D000685:Serum Amyloid A Protein / Q000032:analysis* / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D016896:Treatment Outcome
D051242:Caveolin 1; D009363:Neoplasm Proteins; D017395:Plasminogen Activator Inhibitor 1; D011228:Prealbumin; D000685:Serum Amyloid A Protein